QUINUCLIDINE COMPOUNDS FOR MODULATING ALPHA7-NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY
申请人:Alpharmagen, LLC
公开号:US20170166561A1
公开(公告)日:2017-06-15
Provided are substituted quinuclidine compounds, pharmaceutical compositions comprising such compounds, and methods of modulating α7 nicotinic acetylcholine receptors and treating neurological disorders using such compounds.
US9434724B2
申请人:——
公开号:US9434724B2
公开(公告)日:2016-09-06
[EN] QUINUCLIDINE COMPOUNDS FOR MODULATING ALPHA7 -NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY<br/>[FR] COMPOSÉS DE QUINUCLIDINE POUR MODULER L'ACTIVITÉ DU RÉCEPTEUR NICOTINIQUE ALPHA7 DE L'ACÉTYLCHOLINE
申请人:ALPHARMAGEN LLC
公开号:WO2016007630A1
公开(公告)日:2016-01-14
Provided are substituted quinuclidine compounds, pharmaceutical compositions comprising such compounds, and methods of modulating α7 nicotinic acetylcholine receptors and treating neurological disorders using such compounds.
[EN] INDOLE CARBOXAMIDE COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS<br/>[FR] COMPOSÉS D'INDOLE CARBOXAMIDE ET LEUR UTILISATION POUR LE TRAITEMENT D'INFECTIONS MYCOBACTÉRIENNES
申请人:THE GLOBAL ALLIANCE FOR TB DRUG DEV INC
公开号:WO2021062319A1
公开(公告)日:2021-04-01
Provided herein are compounds of Formula (I) as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of tuberculosis.